In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Stereotaxis (STXS – Research Report), with a price target of $4.00. The company’s shares opened today at $1.84.
Takkinen covers the Healthcare sector, focusing on stocks such as TELA Bio, NeuroPace, and Biolase. According to TipRanks, Takkinen has an average return of -4.7% and a 36.96% success rate on recommended stocks.
Stereotaxis has an analyst consensus of Strong Buy, with a price target consensus of $4.83, which is a 162.50% upside from current levels. In a report released on May 19, B.Riley Financial also maintained a Buy rating on the stock with a $5.50 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.75 and a one-year low of $1.55. Currently, Stereotaxis has an average volume of 258.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stereotaxis, Inc. engages in the design, manufacture, and market of robotic systems and instruments that electrophysiologists use for the treatment of abnormal heart rhythms known as cardiac arrhythmias. Its products include The Epoch Solution, Niobe Magnetic Navigation System, Vdrive Robotic Navigation System, and Odyssey Solution. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Read More on STXS:
- Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms
- Stereotaxis Reports 2023 First Quarter Financial Results
- STXS Upcoming Earnings Report: What to Expect?
- Stereotaxis to Report First Quarter 2023 Financial Results on May 9, 2023
- Over 1,000 Cardiac Patients Treated with Genesis Robotic System
